Jean-Ehrland Ricci, Research Director at Inserm, shared on LinkedIn:
“Mitophagy is everywhere in cancer reviews – but surprisingly rarely tested in vivo.
In our upcoming paper, we directly track mitophagy during KRAS-driven lung tumorigenesis and show that PINK1-dependent mitophagy is activated from the earliest stages of transformation.
Importantly, its role is highly stage-dependent: PINK1 is critical for tumor initiation, largely dispensable once tumors are established, but becomes a vulnerability again under KRAS-targeted therapy.
Mitochondrial quality control may therefore be more than a hallmark of cancer – it may represent an early adaptation and a targetable mechanism of therapeutic resistance.
Kudos to all and specially to Diogo Gonçalves, Emma Guilbaud, Léa Di Mascio, IHU RespirERA and Sandrine Marchetti.”
Title: PINK1-mediated mitophagy supports lung cancer initiation and limits the efficacy of KRAS-targeted therapy
Authors: Diogo Gonçalves, Emma Guilbaud, Léa Di Mascio, Camille Guerrier, Linda Mejri, Sonia Núñez-Vázquez, Lucie Levasseur, Rachel Paul, Corinne Menigot, Christophe Bontoux, Guylène Rignol, Véronique Hofman, Paul Hofman, Marin Truchi, Bernard Mari, Laurent Yvan-Charvet, Johanna Chiche, Sandrine Marchetti, Jean-Ehrland Ricci
Emma Guilbaud, Postdoctoral Associate at Fox Chase Cancer Center, added:
“It was as part of this wonderful team with Sandrine Marchetti and Jean-Ehrland Ricci that my journey in the field of mitochondria and mitophagy began, with this exciting project exploring how PINK1-dependent mitophagy controls lung cancer development.
I’m really grateful to Sandrine, Jean-Ehr and all Team 3 for everything I learned during my PhD and for helping shape the beginning of my scientific career!”
You can also read: FURTHER: Firmonertinib Shows Promising Activity in EGFR PACC-Mutant Advanced NSCLC
